{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:53:35Z","timestamp":1791672815230,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.bcmd.2012.10.007","type":"journal-article","created":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T05:31:13Z","timestamp":1352871073000},"page":"141-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase"],"prefix":"10.1016","volume":"50","author":[{"given":"Inna","family":"Bendikov-Bar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gali","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Filocamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"50","key":"10.1016\/j.bcmd.2012.10.007_bb0005","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/archneur.1993.00540110088009","article-title":"The role of neurogenetics in Gaucher disease","volume":"1993","author":"Brady","year":"1993","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0065-2660(08)60202-3","article-title":"Gaucher disease","volume":"32","author":"Beutler","year":"1995","journal-title":"Adv. Genet."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0015","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2012.10.007_bb0020","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","article-title":"How I treat Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.10.007_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.cellbio.14.1.19","article-title":"Ubiquitin and the control of protein fate in the secretory and endocytic pathways","volume":"14","author":"Bonifacino","year":"1998","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0092-8674(00)81881-4","article-title":"ER quality control: the cytoplasmic connection","volume":"88","author":"Kopito","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2012.10.007_bb0035","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ymgme.2007.10.132","article-title":"Intracellular cholesterol modifies the ERAD of glucocerebrosidase in Gaucher disease patients","volume":"93","author":"Ron","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0050","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pmed.0010021","article-title":"Enzyme replacement in Gaucher disease","volume":"1","author":"Beutler","year":"2004","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0065","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1021\/jm3006178","article-title":"Conformationally-locked N-glycosides with selective beta-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease","volume":"55","author":"Castilla","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0070","doi-asserted-by":"crossref","first-page":"e29861","DOI":"10.1371\/journal.pone.0029861","article-title":"High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase","volume":"7","author":"Goldin","year":"2012","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.bcmd.2012.10.007_bb0075","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cbic.201000323","article-title":"A Fluorescent sp2-iminosugar with pharmacological chaperone activity for gaucher disease: synthesis and intracellular distribution studies","volume":"11","author":"Luan","year":"2010","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.bcmd.2012.10.007_bb0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cmdc.201000469","article-title":"Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease","volume":"6","author":"Oulaidi","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcmd.2012.10.007_bb0085","doi-asserted-by":"crossref","first-page":"10647","DOI":"10.1021\/bi201619z","article-title":"Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-beta-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease","volume":"50","author":"Orwig","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcmd.2012.10.007_bb0090","doi-asserted-by":"crossref","first-page":"5734-548","DOI":"10.1021\/jm300063b","article-title":"Discovery, structure\u2013activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0095","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm300342q","article-title":"Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease","volume":"55","author":"Trapero","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0100","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1039\/c2ob06987c","article-title":"Synthesis of N-substituted epsilon-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease","volume":"10","author":"Wang","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0105","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/jm201633y","article-title":"Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease","volume":"55","author":"Goddard-Borger","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1039\/C1MD00200G","article-title":"Non-iminosugar glucocerebrosidase small molecule chaperones","volume":"3","author":"Marugan","year":"2012","journal-title":"Medchemcomm"},{"key":"10.1016\/j.bcmd.2012.10.007_bb0115","doi-asserted-by":"crossref","first-page":"13192","DOI":"10.1073\/pnas.0705637104","article-title":"Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease","volume":"104","author":"Zheng","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0120","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0125","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","author":"Luan","year":"2012","journal-title":"Brain Dev."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant beta-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0135","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0140","doi-asserted-by":"crossref","first-page":"8647","DOI":"10.1021\/jo801626v","article-title":"Metal-free one-pot oxidative amidation of aldoses with functionalized amines","volume":"73","author":"Colombeau","year":"2008","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0145","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0150","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1111\/j.1742-4658.2006.05410.x","article-title":"Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients","volume":"273","author":"Chang","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0155","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0160","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/jm060677i","article-title":"Isofagomine- and 2,5-anhydro-2,5-imino-d-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention","volume":"50","author":"Yu","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0170","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2011.569162","article-title":"Pharmacological chaperone therapy for Gaucher disease: a patent review","volume":"21","author":"Benito","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0175","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1016\/j.bmcl.2007.08.050","article-title":"N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease","volume":"17","author":"Huang","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0180","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/cbic.200800304","article-title":"Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen\/deuterium exchange mass spectrometry","volume":"9","author":"Tropak","year":"2008","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bcmd.2012.10.007_bb0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ymgme.2008.12.008","article-title":"Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells","volume":"96","author":"Rigat","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0190","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2012.10.007_bb0195","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612001933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612001933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:39Z","timestamp":1761049719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979612001933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1079979612001933"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.10.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}